Narciclasine (Amaryllidaceae Lactam · Ribosome Inhibitor · Antiproliferative Research Lead)
| Compound | Narciclasine (Lycoricidine) |
| Chemical class | Alkaloid — Amaryllidaceae (Isocarbostyril-type; phenanthridine lactam) |
| CAS | 29477-83-6 |
| Primary source | Narcissus spp. (daffodil bulbs), Lycoris spp. |
| Key applications | Antiproliferative (cancer research lead); antifungal; phytotoxic; cytotoxic at low concentrations; informational reference |
| Claim strength | Moderate (preclinical anticancer); Informational only (high cytotoxicity) |
| Typical form | Research compound; not a supplement ingredient; Narcissus/Lycoris extract minor constituent |
| Buy from Herbuno | Browse HerbIQ Compound Index → |
Name origin: From Narcissus (the daffodil genus, named from Greek mythology) + clasis (Greek: breaking/splitting). Narciclasine is a phenanthridine lactam alkaloid — a more complex ring system than lycorine, incorporating a lactam (cyclic amide) that confers distinctive chemical properties and exceptional biological potency. Pharmacological significance: Narciclasine is one of the most potent plant-derived antiproliferative agents discovered — active against cancer cell lines at nanomolar concentrations. Its mechanism: narciclasine inhibits peptidyl transferase activity of the 60S ribosomal subunit (the same step inhibited by cycloheximide), blocking eukaryotic protein synthesis with extraordinary potency. It also inhibits Rho GTPase signalling, disrupting the actin cytoskeleton and interfering with cell division. Toxicity context: Narciclasine is intensely cytotoxic — this broad cytotoxicity at nanomolar concentrations means it damages normal cells alongside cancer cells, limiting its direct therapeutic use. Analogue programmes seeking to widen the therapeutic window are the primary research direction. Phytotoxic activity: Narciclasine is responsible for the allelopathic (growth-inhibitory) properties of daffodil bulbs — inhibiting growth of competing plants. This allelopathic mechanism is the same protein synthesis inhibition that produces the antiproliferative effect in cancer research contexts. Supplement status: Not a supplement ingredient — too cytotoxic for any human exposure context outside of controlled pharmaceutical research.
Narciclasine — Research Context
Ribosome-targeting anticancer mechanism: Narciclasine’s inhibition of the 60S ribosomal peptidyl transferase centre (PTC) at nanomolar concentrations makes it one of the most potent ribosome-targeting natural products known. The structural basis for this potency has been elucidated by cryo-EM studies showing the narciclasine lactam binding in the PTC A-site. This mechanism is distinct from taxol (microtubule stabilisation), camptothecin (topoisomerase I), and vinca alkaloids (tubulin depolymerisation) — making narciclasine scaffolds attractive for drug resistance contexts. Research reference.
Anticancer selectivity research: The broad cytotoxicity challenge has motivated synthetic analogue programmes. Hydroxyphenyl narciclasine analogues, pancratistatin (a narciclasine analogue from Pancratium littorale) with reportedly higher cancer vs normal cell selectivity, and structural modifications of the lactam bridge are under investigation. None has yet reached clinical trials. Claim strength: Moderate (compelling preclinical; no clinical translation yet).
Antifungal activity: Narciclasine inhibits Rho1p GTPase (the yeast equivalent of mammalian Rho GTPase), disrupting cell wall synthesis in fungi. Active against Candida, Aspergillus, and plant pathogenic fungi. The antifungal mechanism relates to its phytotoxic (allelopathic) role in daffodil plants — protecting bulbs from fungal pathogens in soil. Claim strength: Moderate (in vitro).
This compound is documented for research and formulator education purposes. For commercially available botanical ingredients, explore the HerbIQ Compound Index →
Frequently Asked Questions — Narciclasine
Why is narciclasine so much more potent than lycorine?
The lactam ring in narciclasine (vs lycorine’s tertiary amine) creates a more rigid, planar structure that fits the ribosomal PTC with exceptional complementarity. Cryo-EM structural studies show narciclasine forming specific hydrogen bonds within the PTC that lycorine (less potent) does not. The nanomolar potency of narciclasine (vs lycorine’s low micromolar range) reflects this superior ribosome-binding geometry.
What is pancratistatin and how does it relate to narciclasine?
Pancratistatin (from Pancratium littorale, sea daffodil) is a polyhydroxylated narciclasine analogue — structurally similar but with additional hydroxyl groups on the phenanthridine ring. Pancratistatin has attracted considerable research interest as a selectively cancer cell-toxic natural product that reportedly spares normal cells better than narciclasine. However, the evidence for superior selectivity is not consistent across cell systems, and pancratistatin’s clinical development has been hampered by supply (the plant source is limited) and synthetic access challenges.
Does narciclasine cause daffodil bulb poisoning?
Narciclasine contributes to the toxicity of Amaryllidaceae bulb ingestion alongside lycorine and other alkaloids. At the concentrations present in daffodil bulbs (milligram quantities per bulb), narciclasine exposure from accidental ingestion is below its most dramatic cytotoxic effects but may contribute to the mucosal irritation, nausea, and GI symptoms seen in daffodil poisoning. The primary emetic from daffodil poisoning is lycorine; narciclasine’s contribution is secondary.
Is there any research using narciclasine analogues in cancer treatment?
Yes — multiple analogue programmes are underway. Key approaches: (1) pancratistatin analogues with improved selectivity window; (2) narciclasine-antibody conjugates (analogous to ADC approach for cancer targeting); (3) synthesis of lycoricidine (the N-desmethyl narciclasine analogue); (4) computational drug design of narciclasine scaffold derivatives optimising ribosome binding vs cytotoxicity selectivity. None has advanced to Phase I clinical trials yet.
Related compounds: Lycorine, Galantamine, Camptothecin, Colchicine
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery